FOLH1 and prostate carcinoma: Over the last decade, prostate-specific membrane antigen (PSMA) radioligand therapy (RLT) has become a major focus point in the treatment of advanced prostate cancer (PCa), such as for treatment of patients with (metastasized) castration resistant prostate cancer (CRPC).